- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01307982
Comparative Anti-Reflux Procedures in Neurologically Impaired Children (CARPNIC)
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Utah
-
Salt Lake City, Utah, United States, 84113
- Primary Children's Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- patient is between 6 months and 18 years of age; AND
- patient has functional impairment classified by either gross motor functional classification of 3, 4 or 5 OR impaired function in walking, crawling/standing, rolling/sitting, arm use, hand use, ability to hold head up; AND
- patient has a gastrostomy; AND
- patient has intolerance of feedings or other complications attributed to GERD as defined below; AND
patient has a positive GERD diagnostic evaluation as define below:
GERD diagnostic evaluation will include the following investigations;
- endoscopy and biopsy for visual assessment and histology of the esophageal mucosa
- pH study and/or multichannel intraluminal impedance (MII) probe to detect and quantify gastroesophageal reflux
GER demonstrated by:
- Reflux Esophagitis: Endoscopic appearance of mucosal breaks in the distal esophagus with or without pathologist diagnosis based on one or more biopsy histologic features of: inflammatory cellular infiltrate, basal cell hyperplasia, elongation of the vascular papillae AND no infectious microorganisms and < 15 eosinophils per high power field; OR
pH OR pH/multichannel intraluminal impedance(MII) probe evidence of pathologic GER:
- pH probe: acid reflux index > 7 % OR
- pH/MII reflux symptom-associated acid or non-acid volume associated reflux events;
- Upper GI will only be used to determine normal anatomy; AND
patient has either medically refractory GERD or severe GERD as defined below:
Medically refractory GERD - GERD that has not responded to 12 weeks of treatment with a proton pump inhibitor (PPI) (and verified gastric pH > 4) and/or trial of continuous intragastric feedings and has one of the following complications:
- Esophagitis: Endoscopic appearance of mucosal breaks in the distal esophagus with or without pathologist diagnosis based on one or more biopsy histologic features of: inflammatory cellular infiltrate, basal cell hyperplasia, elongation of the vascular papillae
- Failure to thrive: diminishing weight percentile for age or weight for age z-score sustained over 6 months.
- Pneumonia consistent with aspiration,
- Acute life threatening event,
Severe GERD - at least one severe complication of GERD and patient cannot safely tolerate a trial of medical management due to one of the following life-threatening complications:
- aspiration pneumonia,
- acute life threatening event (ALTE),
- complete loss of airway protection (absent cough/gag) AND,
- Upper GI barium contrast study for anatomy; AND
- Barium pharyngeal swallow study or modified barium swallow study or Flexible Endoscopic Evaluation of Swallowing (FEES) in past year; AND
- the parent or legal guardian speaks English or Spanish (the only two languages in which the instruments are standardized)
Exclusion Criteria:
- Upper GI findings that would mandate a fundoplication including: hiatal hernia, esophageal stricture, Barret's esophagus; OR
- Upper GI findings show uncorrected distal gastrointestinal obstruction including: gastric outlet obstruction, duodenal obstruction, malrotation; OR
- Upper GI demonstrates structural foregut abnormalities that preclude a fundoplication including: microgastria, short esophagus, high anesthetic risk; OR
- Diagnosis or history of congenital diaphragmatic hernia, esophageal atresia, chronic intestinal pseudoobstruction; OR
- Endoscopy and biopsy demonstrates esophagitis from causes other than GER including: eosinophilic esophagitis, candida esophagitis, viral esophagitis); OR
- Rapidly changing or indeterminate neurological including either a deteriorating neurological condition such as rapid loss of developmental milestones or improving, such as rapid recovery following severe neurological insult; OR
- Patient has unacceptable general anesthetic risk; OR
- A previous Nissen fundoplication; OR
- Feeds delivered by GJ/NJ at the time of enrollment occurring for greater than 3 months.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Fundoplication
During fundoplication surgery, the upper curve of the stomach (the fundus) is wrapped around the esophagus and sewn into place so that the lower portion of the esophagus passes through a small tunnel of stomach muscle.
This surgery strengthens the valve between the esophagus and stomach (lower esophageal sphincter), which stops acid from backing up into the esophagus as easily.
|
During fundoplication surgery, the upper curve of the stomach (the fundus) is wrapped around the esophagus and sewn into place so that the lower portion of the esophagus passes through a small tunnel of stomach muscle.
This surgery strengthens the valve between the esophagus and stomach (lower esophageal sphincter), which stops acid from backing up into the esophagus as easily.
Other Names:
|
|
Active Comparator: Gastrojejunal (GJ) feeding tube
Gastrojejunal (GJ) tube placement is an image guided technique in which a special soft feeding catheter is placed through an existing hole in the stomach (gastrostomy) into the small bowel (jejunum).
|
Gastrojejunal (GJ) tube placement is an image guided technique in which a special soft feeding catheter is placed through an existing hole in the stomach (gastrostomy) into the small bowel (jejunum).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
GERD-related hospitalization and ED visits
Time Frame: 12 months
|
Parental interviews and chart reviews will be used to record all health care encounters.
Each encounter will be classified as either GERD-related or not.
GERD-related hospitalizations and ED visits will be further classified as; diagnostic testing, procedural problems, likely aspiration pneumonia (AP or bacterial pneumonia), respiratory distress of other etiology, or death from any cause.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Health Related Quality of Life
Time Frame: 12 months
|
These are a series of surveys about the child and caregiver's health related quality of life.
|
12 months
|
|
Total length of stay
Time Frame: 12 months
|
This is the length of stay for each hospitalization and ED visit.
|
12 months
|
|
Complications from treatment
Time Frame: 12 months
|
This will be monitored with hospitalizations (primary outcome)
|
12 months
|
|
Complications from failure of treatment
Time Frame: 12 months
|
This will be monitored with hospitalizations (primary outcome), and will include things such as repeat procedure for fundoplication arm, ongoing need for GERD medications, and treatment cross-over.
|
12 months
|
|
Mortality
Time Frame: 12 months
|
Any cause captured at 28 days and 12 months post procedure.
Procedure related deaths will also be captured.
|
12 months
|
|
Costs related to hospital, ED, outpatient, and home-health care
Time Frame: 12 months
|
This will be abstracted from hospital administrative database.
|
12 months
|
|
Nutritional outcomes
Time Frame: 12 months
|
Nutritional outcomes will be measured through anthropomorphic measurements including:
|
12 months
|
|
Other outpatient health care
Time Frame: 12 months
|
This will include primary care provider, neurology, gastroenterology, surgery, physiotherapy, etc.
|
12 months
|
|
Symptom control
Time Frame: 12 months
|
We will ask parents/caregivers to evaluate their childs symptoms and severity.
|
12 months
|
|
Parental Goals of either treatment for GERD
Time Frame: 12 months
|
We will ask parents/caregivers their goals for treatment and evaluate if they have been met.
|
12 months
|
|
Physician Goals of either treatment for GERD
Time Frame: 12 months
|
We will ask physicians their goals for treatment and evaluate if they have been met.
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Raj Srivastava, MD, MPH, University of Utah
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 00043616
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nervous System Diseases
-
Bracco Diagnostics, IncCompletedCentral Nervous System Neoplasms | Central Nervous System Disease
-
Delve Bio, Inc.Not yet recruiting
-
Bracco Diagnostics, IncCompletedCentral Nervous System Diseases | Central Nervous System NeoplasmsUnited States
-
Bracco Diagnostics, IncCompletedCentral Nervous System Diseases | Central Nervous System NeoplasmsUnited States
-
University of MichiganCompletedAutonomic Peripheral Nervous System DiseasesUnited States
-
UNC Lineberger Comprehensive Cancer CenterRecruitingCentral Nervous System TumorUnited States
-
Washington University School of MedicineRecruitingCentral Nervous SystemUnited States
-
The Hong Kong Polytechnic UniversityUnknownAutonomic Nervous System DisorderChina
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
National Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
Clinical Trials on Fundoplication
-
L. Michael BruntUniversity of Oregon; Northwestern University; Duke University; University of WashingtonCompletedEsophageal AchalasiaUnited States
-
Foregut Research FoundationTerminatedHiatal Hernia Large | Gastro Esophageal Reflux | Hiatal Hernia | Hiatal Hernia, Paraesophageal | Reflux, Gastroesophageal | Reflux AcidUnited States
-
Turku University HospitalCompleted
-
Kuopio University HospitalRecruitingRecurrence | Hiatal Hernia | Paraesophageal HerniaFinland
-
University of Turin, ItalyCompleted
-
University of California, San FranciscoNational Heart, Lung, and Blood Institute (NHLBI)CompletedGastroesophageal Reflux | Idiopathic Pulmonary FibrosisUnited States
-
Institute of Child HealthCompletedGastro-Oesophageal RefluxUnited Kingdom
-
Ain Shams UniversityCompletedGERD - Gastro-Esophageal Reflux DiseaseEgypt
-
Grubnik VolodymyrCompletedGastro Oesophageal Reflux Disease
-
Chinese University of Hong KongUnknownGastroesophageal Reflux DiseaseHong Kong